Andrew Hack
InvestorPartner, Life Sciences at Bain Capital Life Sciences · Board director at Nuvalent
Boston
About
Andrew Hack is a Partner on the Life Sciences team at Bain Capital, which he joined in 2019. He previously served as Chief Financial Officer of Editas Medicine and as a portfolio manager at Millennium Management running a market-neutral healthcare hedge fund, and earlier worked as a securities analyst at healthcare-focused hedge funds and banks and as Director of Life Sciences at Reify Corporation. He holds an MD and PhD in molecular genetics and cell biology and an AB in biology, all from the University of Chicago.
Invests in
Biotech
Board director at Nuvalent
Intro paths
In turn, Andrew can intro founders to Nuvalent's investors below.
Nuvalent's investors · 2
Co-founders at Nuvalent
Deals · 2
Xilio TherapeuticsBoard seat
via Bain Capital Life Sciences · filed Feb 2021 · $95M raise
JenaValveBoard seat
via Bain Capital Life Sciences · filed Oct 2020 · $66.5M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Bain Capital Life Sciences
Frequently asked questions
- Who is Andrew Hack?
- Andrew Hack is a Partner on the Life Sciences team at Bain Capital, which he joined in 2019. He previously served as Chief Financial Officer of Editas Medicine and as a portfolio manager at Millennium Management running a market-neutral healthcare hedge fund, and earlier worked as a securities analyst at healthcare-focused hedge funds and banks and as Director of Life Sciences at Reify Corporation. He holds an MD and PhD in molecular genetics and cell biology and an AB in biology, all from the University of Chicago.
- Where does Andrew Hack work?
- Andrew Hack is Partner, Life Sciences at Bain Capital Life Sciences and Board director at Nuvalent.
- What does Andrew Hack invest in?
- Andrew Hack invests in Biotech.
- What boards does Andrew Hack sit on?
- Andrew Hack holds tracked board seats at JenaValve, Xilio Therapeutics.